Celldex reports Phase 2 ColdU and SD extension data

Celldex presented Phase 2 cold urticaria (ColdU) and symptomatic dermographism open-label extension data reporting that retreatment with barzolvolimab led to rapid improvement in urticaria control after symptom recurrence, shared at the 2026 AAAAI Annual Meeting.

Celldex presented new data from a Phase 2 trial and a symptomatic dermographism open-label extension at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting in Philadelphia. The presentation was a late-breaking poster delivered by Jonathan A. Bernstein, MD, who is identified as a trial investigator and professor at the University of Cincinnati College of Medicine. The company reported that retreatment with barzolvolimab led to rapid improvement in urticaria control after symptoms recurred. Barzolvolimab is described as a humanized monoclonal antibody that targets mast cells. Key findings: - Retreatment with barzolvolimab was reported to produce rapid improvement in urticaria control after symptom recurrence. - Data came from a Phase 2 ColdU (cold urticaria) trial and a symptomatic dermographism open-label extension. - Results were shared in a late-breaking poster at the 2026 AAAAI Annual Meeting in Philadelphia. - The presentation was delivered by Jonathan A. Bernstein, MD, listed as a trial investigator and professor. - Barzolvolimab is described as a humanized monoclonal antibody that targets mast cells, which the company links to the root cause of ColdU and symptomatic dermographism. Summary: The report indicates retreatment with barzolvolimab was reported to produce rapid improvement in urticaria control after recurrence. Undetermined at this time.